Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

European pharmaceutical giant Novo Nordisk (NVO) has struck a licensing deal with U.S. biotech firm Septerna (SEPN) to ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...